COMPARATIVE PHARMACOECONOMIC RESEARCH AND EVALUATION OF ENALAPRIL GENERICS IN TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION
The number of people with cardiovascular diseases has increased significantly in recent years. According to statistics, diseases of the cardiovascular system occupy one of the first places among other diseases. One of the main pathologies in cardiology is hypertension. Treatment of arterial hypertension for a long period remains an important medico-social and economic task, a heavy financial burden falls on the patient himself or on the health care system, in the case of free distribution of drugs. The group of antihypertensive drugs is one of the most expensive, which raises the question of cost-effective therapy. Clinical and economic research that combines analysis of clinical efficacy and affordability is necessary for evidence-based, rather than empirical, choice of the drug. The most acceptable method of assessing the clinical significance of various drugs is a «cost-effectiveness» analysis. The article is devoted to the conducted pharmacoeconomic research, giving a comparative assessment of various enalapril generics. The objective of the work was to identify and justify the use of the most clinically effective and cost-effective generic drugs enalapril. The methodological basis of the research was the modern concept of marketing research of the drug market, the methodology of system analysis and scientific forecasting of economic phenomen. In the process of research, the methods of system, sociological, economic and statistical analysis, including absentee questionnaires, were used. As a result, sales of cardiovascular drugs on the pharmaceutical market were analyzed, the structure of enalapril generic consumption in health facilities was studied, and a pharmacoeconomic analysis («cost-effectiveness» method) of antihypertensive treatment of enalapril generics was conducted.
Belousov Yu. B., Zyryanov S. K. Dzheneriki ili brendyi // Kachestvennaya klin. praktika. – 2003. – № 2. – P. 95–100.
Ivleva A. Ya. Klinicheskoe primenenie ingibitorov angiotenzinprevrashchayushchego fermenta i antagonistov angiotenzina II. // Konsilium. – 2003. – T. 5, № 11. – P. 641–648.
Korzun A. I., Kirillova M. V. Sravnitelnaya harakteristika ingibitorov angiotenzinprevraschayuschego fermenta // Ekologiya cheloveka. – 2003. – № 2. – P. 16–22.
Leonova M. V. Vyibor antigipertenzivnyih preparatov s naimenshey stoimostyu // Farmateka. – 2003. – № 6. – P. 34–38.
Marcevich S. Yu., Shal'nova S. A., Yakusevich V. V. i dr. Nazva stattі // Kardiovaskulyarnaya terapiya i profilaktika. – 2003. – № 2. – P. 33–37.
Nedogoda S. V., Sabanov S. V. Farmakoekonomika arterialnoy gipertenzii: ot globalnogo k chastnomu // Probl. standartizacii v zdravoohranenii. – 2003. – № 2. – P. 25–29.
Abbate A., Biondi-Zoccai G. G. L., Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling // J. Cell. Physiol. – 2002. – N 5. – P. 145–153.
Klingbeil A., Schneider M., Martus P. et al. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension // The Am. J. of Med. – 2003. – Vol. 115. – P. 41–46.
Abstract views: 93 PDF Downloads: 62
This work is licensed under a Creative Commons Attribution 4.0 International License.